167 related articles for article (PubMed ID: 35961201)
1. Tumor-infiltrating neutrophils and peripheral neutrophil-to-lymphocyte ratio conversely predicted the prognosis of patients with non-small cell lung cancer.
Yang R; Wang X; Ma C; Zhang Z; Liu N; Ma X; Zhang Y; Wang X; Liu Y
Cell Immunol; 2022 Sep; 379():104588. PubMed ID: 35961201
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Wang J; Liu Y; Mi X; Shao M; Liu L
Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
[TBL] [Abstract][Full Text] [Related]
4. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
Guo D; Jin F; Jing W; Li M; Chen D; Zou B; Jiang G; Fu L; Zhu H; Kong L; Wu J; Yu J; Yue J
Clin Lung Cancer; 2019 Nov; 20(6):412-419. PubMed ID: 31300364
[TBL] [Abstract][Full Text] [Related]
6. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
7. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study.
Liu W; Ren S; Yang L; Xiao Y; Zeng C; Chen C; Wu F; Hu Y
Int J Surg; 2023 Nov; 109(11):3519-3526. PubMed ID: 37578441
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
[TBL] [Abstract][Full Text] [Related]
9. Prognostic assessment of C‑reactive protein and neutrophil to lymphocyte ratio in patients with non-small cell lung cancer.
Zhao T
Wien Klin Wochenschr; 2022 Oct; 134(19-20):705-711. PubMed ID: 35794490
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer.
Cedrés S; Torrejon D; Martínez A; Martinez P; Navarro A; Zamora E; Mulet-Margalef N; Felip E
Clin Transl Oncol; 2012 Nov; 14(11):864-9. PubMed ID: 22855161
[TBL] [Abstract][Full Text] [Related]
11. Association of intra-tumoral tumour-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio is an independent prognostic factor in non-small cell lung cancer.
Dirican N; Karakaya YA; Gunes S; Daloglu FT; Dirican A
Clin Respir J; 2017 Nov; 11(6):789-796. PubMed ID: 26619201
[TBL] [Abstract][Full Text] [Related]
12. Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer.
Rakaee M; Busund LT; Paulsen EE; Richardsen E; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Kilvaer TK
Oncotarget; 2016 Nov; 7(44):72184-72196. PubMed ID: 27708229
[TBL] [Abstract][Full Text] [Related]
13. The post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapy.
Wang D; Guo D; Li A; Wang P; Teng F; Yu J
Future Oncol; 2020 Mar; 16(9):439-449. PubMed ID: 32141321
[No Abstract] [Full Text] [Related]
14. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
Nakaya A; Kurata T; Yoshioka H; Takeyasu Y; Niki M; Kibata K; Satsutani N; Ogata M; Miyara T; Nomura S
Int J Clin Oncol; 2018 Aug; 23(4):634-640. PubMed ID: 29442281
[TBL] [Abstract][Full Text] [Related]
16. Prognostic analysis of the plasma fibrinogen combined with neutrophil-to-lymphocyte ratio in patients with non-small cell lung cancer after radical resection.
Wang GX; Huang ZN; Ye YQ; Tao SM; Xu MQ; Zhang M; Xie MR
Thorac Cancer; 2023 May; 14(15):1383-1391. PubMed ID: 37037492
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-lymphocyte ratio is a prognostic factor reflecting immune condition of tumor microenvironment in squamous cell lung cancer.
Ohashi K; Nishito Y; Fukuda H; Sadahiro R; Yoshida Y; Watanabe SI; Motoi N; Sonobe Y; Mizuno H; Tsunoda H; Tatsumi K; Suzuki T; Ochiai A; Aoki K
Sci Rep; 2024 Jan; 14(1):429. PubMed ID: 38172491
[TBL] [Abstract][Full Text] [Related]
18. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.
Yan X; Li G
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568
[TBL] [Abstract][Full Text] [Related]
19. Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.
Imai H; Wasamoto S; Tsuda T; Nagai Y; Kishikawa T; Masubuchi K; Osaki T; Miura Y; Umeda Y; Ono A; Minemura H; Yamada Y; Nakagawa J; Kozu Y; Taniguchi H; Ohta H; Kasai T; Kaira K; Kagamu H
Thorac Cancer; 2023 Sep; 14(25):2567-2578. PubMed ID: 37469246
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
